Joseph Geraci
Chief Tech/Sci/R&D Officer presso NETRAMARK HOLDINGS INC.
Patrimonio netto: 932 535 $ in data 31/03/2024
Profilo
Joseph Geraci is the founder of NetraMark Corp., which was founded in 2016.
He holds the title of Chief Executive Officer at NetraMark Corp.
Dr. Geraci's current job is as a Director, Chief Scientific & Technology Officer at NetraMark Holdings, Inc. Dr. Geraci's former job was as the Chief Scientific Officer at Open Source Health, Inc. Dr. Geraci has a doctorate degree from the University of Southern California and graduate and doctorate degrees from the University of Toronto.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
NETRAMARK HOLDINGS INC
6.01% | 28/03/2024 | 4 002 298 ( 6.01% ) | 932 535 $ | 31/03/2024 |
Posizioni attive di Joseph Geraci
Società | Posizione | Inizio |
---|---|---|
NETRAMARK HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 18/10/2021 |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Chief Executive Officer | 01/01/2016 |
Precedenti posizioni note di Joseph Geraci
Società | Posizione | Fine |
---|---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Chief Tech/Sci/R&D Officer | - |
Formazione di Joseph Geraci
University of Southern California | Doctorate Degree |
University of Toronto | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
NETRAMARK HOLDINGS INC. | Technology Services |
Aziende private | 2 |
---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Finance |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Technology Services |
- Borsa valori
- Insiders
- Joseph Geraci